Johnson & Johnson To Present Data From Phase 3 ASTRO Study Of TREMFYA SC Induction Therapy At ECCO; Says Study Achieved Primary And All Secondary Endpoints At Week 12 In Ulcerative Colitis Patients
JNJFebruary 21, 2025
Read more →RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target
JNJFebruary 19, 2025
Read more →Reported Feb. 13, 2025: FDA Announces Heart Pump Recall: Abiomed, Inc. Updates Use Instructions for Impella RP with SmartAssist and Impella RP Flex with SmartAssist Due to A Risk That the Tip of Guidewires or Other Medical Devices May Come into Contact wi
JNJFebruary 14, 2025
Read more →Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
JNJSanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.
February 13, 2025
Read more →Johnson & Johnson Announces New Nipocalimab Data Published In Mabs Journal Details Differentiated Molecular Design, Clinical Profile And Potential Of Nipocalimab To Treat IgG-Driven Alloantibody And Autoantibody Diseases
JNJFebruary 13, 2025
Read more →Sanofi And Janssen Halt Phase 3 E. coli Vaccine Trial Following Interim Analysis Showing Insufficient Efficacy; Sanofi Records €250M Impairment Charge
JNJFebruary 13, 2025
Read more →Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead
JNJJosh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock.
February 12, 2025
Read more →P/E Ratio Insights for Johnson & Johnson
JNJFebruary 12, 2025
Read more →Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates
JNJJohnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ongoing efforts to refine its medtech division.
February 12, 2025
Read more →Johnson & Johnson Initiates Submission Of New Drug Application With FDA For TAR-200 In BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
JNJJanuary 15, 2025
Read more →Looking Into Johnson & Johnson's Recent Short Interest
JNJJanuary 14, 2025
Read more →Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
JNJJohnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.
January 9, 2025
Read more →Johnson & Johnson Says Nipocalimab BLA Received FDA Priority Review Designation For Treatment Of Antibody Positive Patients With Generalized Myasthenia Gravis
JNJJanuary 9, 2025
Read more →Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Mode
JNJNovember 18, 2024
Read more →This Is What Whales Are Betting On Johnson & Johnson
JNJNovember 15, 2024
Read more →CHMP Recommends Approval Of Janssen's Rybrevant (Amivantamab) And Lazcluze (Lazertinib) Combo For First-Line Treatment Of EGFR-Mutated Advanced NSCLC, Potentially Establishing New Standard Of Care Pending European Commission Approval
JNJNovember 15, 2024
Read more →Wolfe Research Initiates Coverage On Johnson & Johnson with Outperform Rating, Announces Price Target of $190
JNJNovember 15, 2024
Read more →Johnson & Johnson's Nipocalimab Achieves Over 77% IgG Reduction And Significant Clinical Improvement In Phase 2 Sjögren's Disease Study; Gains FDA Breakthrough Therapy Designation
JNJNovember 14, 2024
Read more →Johnson & Johnson MedTech Announces Exclusive Commericla Distribution Agreement In U.S. With Responsive Arthroscopy To Expand Sports Soft Tissue Solution
JNJNovember 14, 2024
Read more →Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
JNJNovember 6, 2024
Read more →Expert Ratings For Johnson & Johnson
JNJMay 22, 2024
Read more →RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
JNJMay 22, 2024
Read more →Smart Money Is Betting Big In JNJ Options
JNJMay 21, 2024
Read more →Inquiry Into Johnson & Johnson's Competitor Dynamics In Pharmaceuticals Industry
JNJMay 20, 2024
Read more →Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission
JNJMay 20, 2024
Read more →RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
JNJMay 16, 2024
Read more →Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
JNJJohnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
May 16, 2024
Read more →Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment for $850M Cash and Earnout Consideration
JNJMay 16, 2024
Read more →Johnson & Johnson shares are trading higher after the company reaffirmed 2022 guidance and announced a $5 billion buyback.
JNJSeptember 14, 2022
Read more →US Stocks Could Head For Recovery Today After Inflation-Report-Induced Bloodbath, Futures Trading Suggests — Nikola, JNJ, SoFi In Focus
JNJU.S. stocks could pick up the shreds after the ravages inflicted by an inflation reading that came in more than expected. The major U.S. index futures are pointing to a higher open on Wednesday. On Tuesday, the major U.S. averages recorded their worst single-day declines since the middle of June 2020 amid the COVID-19 pandemic.
September 14, 2022
Read more →Johnson & Johnson Announces $5B Share Repurchase Program
JNJSeptember 14, 2022
Read more →J&J Reaffirms Full-year 2022 Adj. Operational Sales Growth And EPS Guidance Of 6.5%-7.5% And $10.65-$10.75 Per Share, Respectively; Does Not Expect To Incur Debt To Fund Share Repurchase Program
JNJSeptember 14, 2022
Read more →Where Johnson & Johnson Stands With Analysts
JNJOver the past 3 months, 8 analysts have published their opinion on Johnson & Johnson (NYSE:JNJ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
September 12, 2022
Read more →Check Out What Whales Are Doing With JNJ
JNJA whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.
September 12, 2022
Read more →Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to $173
JNJSeptember 12, 2022
Read more →Johnson & Johnson Reaches $300M Settlement In Australian Pelvic Mesh Lawsuit
JNJSeptember 12, 2022
Read more →J&J's 'Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer'
JNJApril 28, 2022
Read more →